Novartis has notified the state of New York of its 83-employee layoff beginning Dec. 31 at its plant in Suffern, NY, a facility that will close in 2016, at which point essentially all traces of it will be eliminated.
India's 20 largest drug manufacturers are forecast to boost their plant investments by 40% by 2017-18, to more than Rs 50,000 crore ($8.3 billion), as they look to improve quality and chase new patent expirations.
Merck is investing €80 million ($107.67 million) in a new plant in China to make treatments for diabetes and other conditions and to realize its aspirations there. But it appears it is looking to India as a way to cut production costs on some of its older products.
When the sterile injectables plant Hospira is building in Vizag, India, opens, perhaps yet this year, the company expects the 1.1-million-square-foot manufacturing facility to add capacity at a lower operating cost. But a plant of that size requires a lot of workers, and so Hospira is also making plans to train the people it needs there.
Contract manufacturer ProBioGen is joining a growing list of companies that are expanding their biologics manufacturing capabilities as more drugmakers need production expertise for cell-based drugs.
Germany's Aenova has been in expansion mode. It pumped up production capacity with its acquisition last year of contract manufacturer Haupt Pharma and has now bought a U.S. company to help it boost its packaging capabilities.
India's Cipla, which has recently been taking steps to expand its capacity outside of its home country, is now boosting its domestic operations. The drugmaker says it is buying two facilities from one of its contractors.
Xellia Pharmaceuticals has laid out expansion plans for its new U.S. facility only two months after establishing a foothold in the country by acquiring a manufacturing facility from Fresenius Kabi. In exchange, the city of Raleigh, NC will bless the the Denmark-based company with a tax break.
Pennsylvania-based West Pharmaceutical is again looking east for expansion. The maker of glass products for the pharma biz, which recently opened a plant in India, is now looking at adding a facility in Ireland that could run to €100 million.
Grand River Aseptic Manufacturing (GRAM), a small parenteral contract manufacturing company in Grand Rapids, MI, has opened a new 28,000-square-foot facility for its finishing operations, inspection services and storage, as well as housing a substantially larger lab, Contract Pharma reports.